Latest & greatest articles for hypertension

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hypertension or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hypertension and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hypertension

38. Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension

Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension 30217371 2018 09 15 1879-1913 2018 Aug 04 The American journal of cardiology Am. J. Cardiol. Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension. S0002-9149(18)31494-2 10.1016/j.amjcard.2018.07.022 Two post hoc analyses in self-identified black and white patients with hypertension evaluated the angiotensin II (...) . Ferdinand Keith C KC Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, Louisiana. Electronic address: kferdina@tulane.edu. Bakris George L GL ASH Comprehensive Hypertensive Center, University of Chicago Medicine, Chicago, Illinois. Cushman William C WC Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee. Weber Michael A MA Department of Medicine, SUNY Downstate School of Medicine, Brooklyn, New York. Lloyd Eric E

EvidenceUpdates2018

39. Cardiovascular risk model performance in women with and without hypertensive disorders of pregnancy

Cardiovascular risk model performance in women with and without hypertensive disorders of pregnancy 30209122 2018 09 13 1468-201X 2018 Sep 12 Heart (British Cardiac Society) Heart Cardiovascular risk model performance in women with and without hypertensive disorders of pregnancy. heartjnl-2018-313439 10.1136/heartjnl-2018-313439 Compare the predictive performance of Framingham Risk Score (FRS), Pooled Cohort Equations (PCEs) and Systematic COronary Risk Evaluation (SCORE) model between women (...) with and without a history of hypertensive disorders of pregnancy (hHDP) and determine the effects of recalibration and refitting on predictive performance. We included 29 751 women, 6302 with hHDP and 17 369 without. We assessed whether models accurately predicted observed 10-year cardiovascular disease (CVD) risk (calibration) and whether they accurately distinguished between women developing CVD during follow-up and not (discrimination), separately for women with and without hHDP. We also recalibrated

EvidenceUpdates2018

40. Optimal Systolic Blood Pressure Target in Apparent Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from Sprint and ACCORD

Optimal Systolic Blood Pressure Target in Apparent Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from Sprint and ACCORD 30142317 2018 09 25 1555-7162 2018 Aug 22 The American journal of medicine Am. J. Med. Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORD. S0002-9343(18)30783-6 10.1016/j.amjmed.2018.08.005 Prior studies suggest benefits of blood pressure lowering (...) on cardiovascular risk may be attenuated in patients with resistant hypertension compared with the general hypertensive population, but prospective data are lacking. We assessed intensive (<120 mm Hg) versus standard (<140 mm Hg) systolic blood pressure targets on adverse outcome risk according to baseline resistant hypertension status, using Action to Control Cardiovascular Risk in Diabetes (ACCORD) and Systolic Blood Pressure Intervention Trial (SPRINT) patient-level data. Patients were categorized as having

EvidenceUpdates2018